Antengene
Help people with cancer
live longer and better.
About us

About Us

Company Introduction

About 3D Medicines

3D Medicines Inc. is a commercialization stage bio-pharmaceutical company, focused on the field of cancer treatment. With a mission to help people with cancer live longer and better, we commit to developing a new generation of therapies for cancer patients around the world, following a future when cancer is managed as a chronic disease. Our differentiated or world-leading portfolio of 12 drug candidates with clinical benefit includes eight in clinical or commercialization stage. Our global first subcutaneously-injectable PD-L1 antibody Envafolimab co-developed by partner has submitted BLA in China. The global first-in-class peptide cancer vaccine 3D189 and GAS6 decoy protein 3D229 are in an ongoing global Phase III trial. Our in-house developed multi-target kinase inhibitor 3D011 has also entered clinical development. We currently have a strong international team of R&D, manufacture and commercialization members. 

Company Introduction

OUR STRENGTHS

  • 01
    Unique strategy surrounding cancer chronicization

    Unique strategy surrounding cancer chronicization

    - Building unique eco-system and entry barrier surrounding cancer chronicization by leveraging our deep insights on patients, products and market

  • 02
    Diversified pipeline with multiple pillars

    Diversified pipeline with multiple pillars

    - First subcutaneous injection PD-L1 mAb worldwide to meet the needs in a huge potential market

    - Diversified late stage pipeline powered by mono and combo therapy, realizing deep synergy among products and targeting a broad patient group

  • 03
    Strong R&D capacity and complete quality system

    Strong R&D capacity and complete quality system

    - Extremely capable clinical team, having submitted NDA in less than 4 years after the launch of Phase I trial, NDA is accepted by NMPA recently

    - Complete capacity from pre-clinical discovery to commercialization, which can be quickly and efficiently expanded

  • 04
    Experienced and comprehensive management team

    Experienced and comprehensive management team

    - Management team with rich experience, covering preclinical discovery, translational medicine, clinical development and commercialization

  • 05
    Global coverage

    Global coverage

    - China-based with global coverage, mobilize various resources while based in China

Best-in-class R&D team

  • R&D staff

    Account for about 70% of total employees

  • R&D team

    PhD: 30%, Master: 39%, Bachelor: 17%

  • Clinical development team

    PhD: 7%, Master: 28%, Bachelor: 64%

STRATEGIC PLANNING

Seizing the cancer chronicization trend, we develop next-generation anticancer solutions

with our backbone IO combination therapy

  1. · Past ·
    Build Core Abilities

    - Establishing an international R&D team with rich experience and holistic approaches

    - Discovering market and patient needs and developing corresponding therapies

    - Developing and registering first subcutaneous injection PD-L1 mAb worldwide

  2. · Present ·
    Scale up

    - Commercializing through external production and sales partnerships

    - Expanding the pipeline through in-house R&D and licensed-in assets

    - Building self-production site, ensuring stable drug supply

  3. · Near Future ·
    Become a Global Pharma

    - Accelerating clinical trials worldwide

    - Penetrating international markets

    - Building a global pharma integrating research, production, and marketing